Postoperative Constipation and Ileus
Postoperative constipation and ileus are common after major pelvic and abdominal GU surgery — particularly cystectomy with urinary diversion, large reconstructive prolapse and fistula repairs, and open pelvic procedures — and are driven by perioperative opioid exposure, intraoperative bowel manipulation, inflammatory signaling, autonomic dysregulation, electrolyte shifts, and reduced mobility.[1][2] Return of bowel function is a key ERAS discharge criterion and one of the most consistent drivers of length of stay, 30-day readmission, and patient-reported recovery after pelvic GU surgery.[1][3] Opioid-induced constipation (OIC) deserves specific attention: it has a distinct peripheral pathophysiology and is the target of peripherally acting μ-opioid receptor antagonists (PAMORAs), which improve bowel function without reversing central analgesia.[4][5]
Bowel Preparation
The historical practice of mechanical bowel preparation (MBP) before pelvic GU surgery has been largely abandoned for most indications. Randomized and observational data in radical cystectomy with urinary diversion show no reduction in infectious or anastomotic complications with MBP, and a signal toward increased electrolyte derangement, dehydration, and delayed return of bowel function.[6][7] Contemporary ERAS protocols for cystectomy explicitly recommend against routine MBP.[2]
In colorectal surgery, by contrast, the evidence now favors combined oral antibiotic preparation plus MBP to reduce surgical site infection and anastomotic leak.[8] This colorectal evidence does not extend to urinary diversion, and should not be extrapolated to GU reconstruction.
| Scenario | Recommendation |
|---|---|
| Radical cystectomy with ileal/colonic urinary diversion | No MBP (ERAS, strong recommendation) |
| Urethral, prolapse, or incontinence surgery | No MBP |
| Reconstruction with planned bowel resection/anastomosis (colonic conduit, continent cutaneous diversion using colon) | Individualize — consider MBP + oral antibiotics per colorectal evidence[8] |
| Planned concomitant colorectal resection | MBP + oral antibiotics[8] |
Prophylactic Bowel Regimens
Multimodal prophylaxis is standard within ERAS pathways and is initiated in the immediate postoperative period.[1][3]
| Intervention | Mechanism / Rationale | Typical Use |
|---|---|---|
| Opioid-sparing analgesia (regional blocks, ketorolac, acetaminophen, gabapentinoids, lidocaine infusion) | Reduces the dominant iatrogenic driver of OIC and ileus | All patients; cornerstone of ERAS |
| Early oral intake | Stimulates gut motility; reduces ileus | POD 0–1 as tolerated |
| Early mobilization | Associated with faster return of bowel function | POD 0 |
| Chewing gum | Sham feeding triggers vagally-mediated motility; modest meta-analytic benefit | Low-cost adjunct |
| Stool softeners (docusate) | Weak evidence for benefit as monotherapy | Often used but not guideline-recommended |
| Osmotic laxatives (PEG, magnesium) | Reliable softening; strong evidence in chronic constipation, limited in acute postop setting | Reasonable if no BM by POD 2–3 |
| Stimulant laxatives (bisacodyl, senna) | Promote propagating contractions | Rescue therapy if no BM by POD 2–3 |
| Alvimopan (PAMORA, oral) | Peripheral μ-antagonism; accelerates GI recovery after bowel resection | Cystectomy with diversion — FDA-approved, REMS-restricted 15-dose inpatient course |
In the pivotal multicenter RCT of patients undergoing radical cystectomy with diversion, alvimopan accelerated return of GI function by ~1 day and reduced length of stay and postoperative ileus events compared with placebo without increased cardiovascular risk.[5] The drug is restricted to short-term inpatient use (≤15 doses) under a REMS program due to a cardiovascular signal in chronic outpatient opioid use.
Opioid-Induced Constipation (OIC)
Pathophysiology
OIC is mediated by μ-opioid receptors on the enteric nervous system and smooth muscle of the GI tract. μ-agonism inhibits propulsive motility, increases nonpropulsive segmentation, reduces fluid secretion and bicarbonate, and increases anal sphincter tone — producing hard stools, delayed transit, and difficult evacuation.[4] Unlike central opioid effects, tolerance to the peripheral GI effects does not develop, so OIC persists throughout exposure.
Definition
OIC is a change in baseline bowel habits associated with opioid therapy, including reduced frequency, worsened straining, sensation of incomplete evacuation, or harder stool form.[9]
Management — AGA Guideline (2019)
The 2019 AGA guideline on medical management of OIC outlines a stepwise approach.[9]
| Step | Agent | Notes |
|---|---|---|
| 1 | Traditional laxatives (PEG, stimulants) | First-line; inexpensive; effective in many patients |
| 2 | PAMORAs — naldemedine, naloxegol, methylnaltrexone | For patients with inadequate response to laxatives; target peripheral μ-receptors without reversing analgesia |
| 3 | Lubiprostone | Chloride channel activator; FDA-approved for OIC in non-cancer pain |
| — | Combination opioids (e.g., oxycodone/naloxone) | Limited US availability |
PAMORAs are contraindicated in known or suspected mechanical bowel obstruction and should be used cautiously in patients with GI disease that increases perforation risk (e.g., diverticulitis, peritoneal malignancy with advanced GI involvement). This is particularly relevant in the postoperative GU setting, where ileus and early obstruction must be excluded before PAMORA administration.[9]
PAMORA Summary
| Agent | Route | Typical Dose | Key Use |
|---|---|---|---|
| Alvimopan | PO | 12 mg BID × up to 15 doses | Inpatient postop GI recovery (cystectomy, bowel resection); REMS-restricted |
| Methylnaltrexone | SC or PO | 0.15 mg/kg SC every other day; 450 mg PO daily | Advanced illness OIC; refractory inpatient OIC |
| Naloxegol | PO | 12.5–25 mg daily | Chronic noncancer OIC |
| Naldemedine | PO | 0.2 mg daily | Chronic OIC in cancer and noncancer pain |
Ileus vs Obstruction
Postoperative ileus (POI) is a functional disturbance of coordinated GI motility; mechanical small-bowel obstruction (SBO) is a structural blockage. The two can be difficult to distinguish in the early postoperative window, and their management diverges sharply.
Definitions and Timing
- Normal postoperative GI dysfunction: transient motility suppression resolving by ~72 hours after major abdominal surgery.
- Prolonged postoperative ileus (PPOI): absence of return of GI function beyond 3–5 days, typically defined by ≥2 of: nausea/vomiting, inability to tolerate oral diet, absence of flatus, abdominal distension, radiographic evidence.[10]
- Early postoperative small-bowel obstruction (EPSBO): mechanical obstruction occurring within 30 days of surgery, most often from adhesions, internal hernia, port-site hernia, or anastomotic edema/stricture.
Clinical and Imaging Differentiation
| Feature | Postoperative Ileus | Mechanical SBO |
|---|---|---|
| Onset | Immediate and gradually resolves | After initial return of function, often after diet advancement |
| Pain | Vague, continuous | Crampy, colicky, intermittent |
| Bowel sounds | Hypoactive/absent | Hyperactive, high-pitched early; absent late |
| Flatus/stool | Reduced diffusely | Absent after transition point |
| Plain film | Gas in small and large bowel; no transition point | Dilated proximal loops, air-fluid levels, decompressed distal bowel, transition point |
| CT with oral/IV contrast | No transition point; diffuse dilation; pneumatosis absent | Discrete transition point; potentially closed-loop signs, mesenteric edema, pneumatosis in strangulation |
| Response to bowel rest/NGT | Slow improvement over days | No resolution; often worsens |
Management
- POI: bowel rest, nasogastric decompression only if symptomatic distension or vomiting, correction of electrolytes (K, Mg, Ca), minimize opioids, ambulate, reassess daily. PAMORAs are appropriate where indicated (e.g., alvimopan post-cystectomy). Imaging if no improvement by POD 5 or clinical concern.
- EPSBO: NPO, NG decompression, IV fluid resuscitation, serial exams, CT imaging. Most adhesive EPSBO resolves nonoperatively within 10–14 days, but closed-loop, ischemic, or progressively worsening obstruction mandates urgent reoperation.
Closed-loop obstruction (two points of obstruction isolating a bowel segment) is a surgical emergency and can be mistaken for ileus. Red flags include disproportionate pain, localized tenderness, leukocytosis, acidosis, rising lactate, and CT findings of mesenteric edema, reduced bowel-wall enhancement, or pneumatosis. Low threshold for reoperation.
Stimulation and Rescue Protocols
A typical pelvic GU postoperative bowel protocol:
- POD 0–1: opioid-sparing analgesia, early ambulation, sips of clear liquids advancing as tolerated, chewing gum if able. Alvimopan per protocol in cystectomy.
- POD 1–2: begin scheduled docusate ± senna; encourage oral intake; ambulation 3–4×/day.
- POD 2–3 without BM: add PEG 17 g PO daily and/or bisacodyl 10 mg PO or PR.
- POD 3 without BM: bisacodyl suppository or phosphate enema if safe; exclude fecal impaction on DRE; reassess for ileus vs mechanical obstruction.
- Refractory OIC on scheduled opioids: methylnaltrexone 0.15 mg/kg SC (after excluding mechanical obstruction); reassess analgesic regimen and minimize opioid exposure.
- Escalation: persistent symptoms ≥ POD 5 → obtain CT with oral/IV contrast; involve general/colorectal surgery if mechanical obstruction suspected.
Pharmacology Hub Companions
For drug-class pharmacology — agent-by-agent mechanism, dose, evidence, safety ceilings — see the two companion hubs:
| Topic | Where it lives |
|---|---|
| Workflow: bowel-prep decision by procedure type, ERAS prophylactic regimen, stepped management of established ileus, broader PAMORA framework | This article |
| Drug-class pharmacology of PEG, sodium phosphate, oral antibiotics, Nichols protocol, APhN boxed warning | Pharmacology: Bowel preparation |
| Drug-class pharmacology of alvimopan, metoclopramide, neostigmine (ACPO), bisacodyl, docusate, simethicone | Pharmacology: Post-op bowel & ileus management |
References
1. Gustafsson UO, Scott MJ, Hubner M, et al. "Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations: 2018." World J Surg. 2019;43(3):659-695. doi:10.1007/s00268-018-4844-y
2. Cerantola Y, Valerio M, Persson B, et al. "Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS®) society recommendations." Clin Nutr. 2013;32(6):879-887. doi:10.1016/j.clnu.2013.09.014
3. Hedrick TL, McEvoy MD, Mythen MG, et al. "American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on Postoperative Gastrointestinal Dysfunction Within an Enhanced Recovery Pathway for Elective Colorectal Surgery." Anesth Analg. 2018;126(6):1896-1907. doi:10.1213/ANE.0000000000002742
4. Viscusi ER, Gan TJ, Leslie JB, et al. "Peripherally acting mu-opioid receptor antagonists and postoperative ileus: mechanisms of action and clinical applicability." Anesth Analg. 2009;108(6):1811-1822. doi:10.1213/ane.0b013e31819e0d3a
5. Lee CT, Chang SS, Kamat AM, et al. "Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial." Eur Urol. 2014;66(2):265-272. doi:10.1016/j.eururo.2014.02.036
6. Large MC, Kiriluk KJ, DeCastro GJ, et al. "The impact of mechanical bowel preparation on postoperative complications for patients undergoing cystectomy and urinary diversion." J Urol. 2012;188(5):1801-1805. doi:10.1016/j.juro.2012.07.039
7. Xu R, Zhao X, Zhong Z, Zhang L. "No advantage is gained by preoperative bowel preparation in radical cystectomy and ileal conduit: a randomized controlled trial of 86 patients." Int Urol Nephrol. 2010;42(4):947-950. doi:10.1007/s11255-010-9732-9
8. Rollins KE, Javanmard-Emamghissi H, Acheson AG, Lobo DN. "The role of oral antibiotic preparation in elective colorectal surgery: a meta-analysis." Ann Surg. 2019;270(1):43-58. doi:10.1097/SLA.0000000000003145
9. Crockett SD, Greer KB, Heidelbaugh JJ, et al. "American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation." Gastroenterology. 2019;156(1):218-226. doi:10.1053/j.gastro.2018.07.016
10. Vather R, Trivedi S, Bissett I. "Defining postoperative ileus: results of a systematic review and global survey." J Gastrointest Surg. 2013;17(5):962-972. doi:10.1007/s11605-013-2148-y